Genmab — Oktober 2020

[Bulder]

Her står jeg på bakkens top og ser mit land er skide smukt. Jeg har ...aaahhh

[AaBforever]

Nå den holdt da over 2200....ikke meget..

[AaBforever]

Jeps...og en ny dag truer i morgen...inden vi får fred i et par dage;-)

[Helge_LarsenPI-redaktør]

USA/Pelosi: Vi er næsten i mål med
hjælpepakke https://www.proinvestor.com/investornyt/668889/usa-pelosi-vi-er-naesten-i-mal-med-hjaelpepakke

[Helge_LarsenPI-redaktør]

NBI. https://indexes.nasdaqomx.com/Index/Overview/NBI

[BioShare]

Tak, synes det hele hænger lidt Helge

[Helge_LarsenPI-redaktør]

God morgen.

[Helge_LarsenPI-redaktør]

Asien: Små stigninger under generel lav omsætninghttps://www.proinvestor.com/investornyt/668901/asien-sma-stigninger

[Helge_LarsenPI-redaktør]

Fredagens aviser med Falck, Danske Bank og
Huscompaniethttps://www.proinvestor.com/investornyt/668900/fredagens-aviser-med-falck-danske-bank-og-huscompaniet

[Plimsoller]

God morgen

[bibob]

God morgen.

[bibob]

OncLive. https://www.onclive.com/view/cd38-directed-regimens-take-reign-in-relapsed-refractory-myeloma-treatment?utm_source=sfmc&utm_medium=email&utm_campaign=10-22-20_CEL-20-OGD0756_OncLiveSS_Multiple Myeloma CC eNews_Revlimid, Celgene_NON_US_Send&eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==

[bibob]

OncLive. https://www.onclive.com/view/quadruplet-regimens-seek-to-raise-the-bar-in-frontline-multiple-myeloma?utm_source=sfmc&utm_medium=email&utm_campaign=10-22-20_CEL-20-OGD0756_OncLiveSS_Multiple Myeloma CC eNews_Revlimid, Celgene_NON_US_Send&eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==

[bibob]

Just a moment...

(www.onclive.com)

[Helge_LarsenPI-redaktør]

Aktier/tendens: Nordea løber med opmærksomheden i ventet grøn starthttps://www.proinvestor.com/investornyt/668910/aktier-tendens-nordea-lober-med-opmaerksomheden-i-ventet-gron-start

[Stroka]

Stadig ikke megen saft og kraft i Genmab-aktien. Det gælder også mange andre pharma- og biotekaktier i disse dage.

[gentogen]

Egentlig ikke en nyhed, men faldt over denne: Daratumumab potentiates the antitumor activity of CHOP and R-CHOP in MCL and FL xenografts. Furthermore, in a patient-derived DLBCL xenograft model, daratumumab anti-tumor activity was comparable to R-CHOP and the addition of daratumumab to either CHOP or R-CHOP led to full tumor regression.

[gentogen]

our findings warrant further clinical development of daratumumab in NHL providing a strong rationale for examining its clinical efficacy in different scenarios, including maintenance therapy after induction therapy, cases with anti-CD20 resistance, FL histologic transformation, and as frontline in combination with the standard of care (CHOP/ R-CHOP)

[gentogen]

Haematologica. 2020 Apr; 105(4)

[gentogen]

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens